Peripheral opioid analgesia in experimental human pain models

This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) bec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain (London, England : 1878) England : 1878), 2003-05, Vol.126 (5), p.1092-1102
Hauptverfasser: Tegeder, Irmgard, Meier, Silke, Burian, Maria, Schmidt, Helmut, Geisslinger, Gerd, Lötsch, Jörn
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1102
container_issue 5
container_start_page 1092
container_title Brain (London, England : 1878)
container_volume 126
creator Tegeder, Irmgard
Meier, Silke
Burian, Maria
Schmidt, Helmut
Geisslinger, Gerd
Lötsch, Jörn
description This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) because M6G does not pass the blood–brain barrier during this time in amounts sufficient to induce CNS effects. The lack of central opioid effects of M6G was confirmed by a lack of change of the pupil size and absence of other opioid‐related CNS effects. As a positive control, morphine was infused at a dosage that definitely produced CNS effects. This was evident by a rapid decrease of the pupil size and by other typical opioid‐related side effects including nausea, vomiting, itchiness, hiccup and sedation. Three different pain models were employed to evaluate the analgesic effects: (i) cutaneous inflammatory hyperalgesia induced by briefly freezing a small skin area to –30°C (‘freeze lesion’); (ii) muscle hyperalgesia induced by a series of concentric and eccentric muscle contractions (DOMS model; delayed onset of muscle soreness); and (iii) pain induced by electrical current (5 Hz sinus stimuli of 0–10 mA). M6G significantly reduced cutaneous hyperalgesia in the ‘freeze lesion’ model as assessed with von Frey hairs. It also reduced muscle hyperalgesia in the DOMS model. Electrical pain, however, was not affected by M6G. Morphine was significantly more active in the ‘freeze lesion’ and DOMS model, and also significantly increased the electrical pain threshold and tolerance. Subcutaneous tissue concentrations of M6G and morphine as assessed with microdialysis were about half those of the respective plasma concentrations. The results of the study indicate that M6G has antihyperalgesic effects in inflammatory pain through activation of peripheral opioid receptors. Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic.
doi_str_mv 10.1093/brain/awg115
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73182419</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19400777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-6849b7e1c57928da37cb4b95a72fba233e5b3e5bc15bb3f62351e98f24441aa03</originalsourceid><addsrcrecordid>eNqF0M9LHDEUwPFQlLra3nouQ8GeOjUvPycHDyK1KwhaWqX0El5mMxo7v0x20P73Zt1FoRcP4R3y4YV8CfkA9CtQww9cxNAf4P01gHxDZiAULRlItUVmlFJVVkbSHbKb0i2lIDhTb8kOMGUoFWZGDi98DOONj9gWwxiGsCiwx_bap4BF6Av_MGbQ-X6Zwc3UYV-M-b2iGxa-Te_IdoNt8u83c49cnnz7dTwvz86_nx4fnZW10GpZqkoYpz3UUhtWLZDr2glnJGrWOGSce-lWpwbpHG8U4xK8qRomhABEyvfI5_XeMQ53k09L24VU-7bF3g9TsppDxQSYVyEYQanWOsNP_8HbYYr55ysjcyYqV9u-rFEdh5Sib-yYW2D8Z4HaVXz7FN-u42f-cbNzcp1fvOBN7Qz2NwBTjW0Tsa9DenHCMDAVZFeuXUhL__B8j_GvVZpraee__9j51Q8pjVL2J38EgkCcAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195432059</pqid></control><display><type>article</type><title>Peripheral opioid analgesia in experimental human pain models</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tegeder, Irmgard ; Meier, Silke ; Burian, Maria ; Schmidt, Helmut ; Geisslinger, Gerd ; Lötsch, Jörn</creator><creatorcontrib>Tegeder, Irmgard ; Meier, Silke ; Burian, Maria ; Schmidt, Helmut ; Geisslinger, Gerd ; Lötsch, Jörn</creatorcontrib><description>This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) because M6G does not pass the blood–brain barrier during this time in amounts sufficient to induce CNS effects. The lack of central opioid effects of M6G was confirmed by a lack of change of the pupil size and absence of other opioid‐related CNS effects. As a positive control, morphine was infused at a dosage that definitely produced CNS effects. This was evident by a rapid decrease of the pupil size and by other typical opioid‐related side effects including nausea, vomiting, itchiness, hiccup and sedation. Three different pain models were employed to evaluate the analgesic effects: (i) cutaneous inflammatory hyperalgesia induced by briefly freezing a small skin area to –30°C (‘freeze lesion’); (ii) muscle hyperalgesia induced by a series of concentric and eccentric muscle contractions (DOMS model; delayed onset of muscle soreness); and (iii) pain induced by electrical current (5 Hz sinus stimuli of 0–10 mA). M6G significantly reduced cutaneous hyperalgesia in the ‘freeze lesion’ model as assessed with von Frey hairs. It also reduced muscle hyperalgesia in the DOMS model. Electrical pain, however, was not affected by M6G. Morphine was significantly more active in the ‘freeze lesion’ and DOMS model, and also significantly increased the electrical pain threshold and tolerance. Subcutaneous tissue concentrations of M6G and morphine as assessed with microdialysis were about half those of the respective plasma concentrations. The results of the study indicate that M6G has antihyperalgesic effects in inflammatory pain through activation of peripheral opioid receptors. Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic.</description><identifier>ISSN: 0006-8950</identifier><identifier>EISSN: 1460-2156</identifier><identifier>DOI: 10.1093/brain/awg115</identifier><identifier>PMID: 12690049</identifier><identifier>CODEN: BRAIAK</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Analgesics - therapeutic use ; Anesthesia ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Cold Temperature - adverse effects ; Cross-Over Studies ; DOMS = delayed onset of muscle soreness ; Double-Blind Method ; Electric Stimulation ; Female ; Humans ; Hyperalgesia - drug therapy ; Hyperalgesia - etiology ; inflammation ; Local anesthesia. Pain (treatment) ; M6G = morphine‐6‐glucuronide ; Male ; Medical sciences ; Morphine ; Morphine Derivatives - therapeutic use ; morphine‐6‐glucuronide ; Muscle Contraction ; pain ; Peripheral Nerves - drug effects ; Peripheral Nerves - metabolism ; peripheral opioid receptor ; Receptors, Opioid - drug effects ; VAS = visual analogue scale</subject><ispartof>Brain (London, England : 1878), 2003-05, Vol.126 (5), p.1092-1102</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) May 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-6849b7e1c57928da37cb4b95a72fba233e5b3e5bc15bb3f62351e98f24441aa03</citedby><cites>FETCH-LOGICAL-c476t-6849b7e1c57928da37cb4b95a72fba233e5b3e5bc15bb3f62351e98f24441aa03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14921981$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12690049$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tegeder, Irmgard</creatorcontrib><creatorcontrib>Meier, Silke</creatorcontrib><creatorcontrib>Burian, Maria</creatorcontrib><creatorcontrib>Schmidt, Helmut</creatorcontrib><creatorcontrib>Geisslinger, Gerd</creatorcontrib><creatorcontrib>Lötsch, Jörn</creatorcontrib><title>Peripheral opioid analgesia in experimental human pain models</title><title>Brain (London, England : 1878)</title><addtitle>Brain</addtitle><description>This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) because M6G does not pass the blood–brain barrier during this time in amounts sufficient to induce CNS effects. The lack of central opioid effects of M6G was confirmed by a lack of change of the pupil size and absence of other opioid‐related CNS effects. As a positive control, morphine was infused at a dosage that definitely produced CNS effects. This was evident by a rapid decrease of the pupil size and by other typical opioid‐related side effects including nausea, vomiting, itchiness, hiccup and sedation. Three different pain models were employed to evaluate the analgesic effects: (i) cutaneous inflammatory hyperalgesia induced by briefly freezing a small skin area to –30°C (‘freeze lesion’); (ii) muscle hyperalgesia induced by a series of concentric and eccentric muscle contractions (DOMS model; delayed onset of muscle soreness); and (iii) pain induced by electrical current (5 Hz sinus stimuli of 0–10 mA). M6G significantly reduced cutaneous hyperalgesia in the ‘freeze lesion’ model as assessed with von Frey hairs. It also reduced muscle hyperalgesia in the DOMS model. Electrical pain, however, was not affected by M6G. Morphine was significantly more active in the ‘freeze lesion’ and DOMS model, and also significantly increased the electrical pain threshold and tolerance. Subcutaneous tissue concentrations of M6G and morphine as assessed with microdialysis were about half those of the respective plasma concentrations. The results of the study indicate that M6G has antihyperalgesic effects in inflammatory pain through activation of peripheral opioid receptors. Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic.</description><subject>Adult</subject><subject>Analgesics - therapeutic use</subject><subject>Anesthesia</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Cold Temperature - adverse effects</subject><subject>Cross-Over Studies</subject><subject>DOMS = delayed onset of muscle soreness</subject><subject>Double-Blind Method</subject><subject>Electric Stimulation</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperalgesia - drug therapy</subject><subject>Hyperalgesia - etiology</subject><subject>inflammation</subject><subject>Local anesthesia. Pain (treatment)</subject><subject>M6G = morphine‐6‐glucuronide</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Morphine</subject><subject>Morphine Derivatives - therapeutic use</subject><subject>morphine‐6‐glucuronide</subject><subject>Muscle Contraction</subject><subject>pain</subject><subject>Peripheral Nerves - drug effects</subject><subject>Peripheral Nerves - metabolism</subject><subject>peripheral opioid receptor</subject><subject>Receptors, Opioid - drug effects</subject><subject>VAS = visual analogue scale</subject><issn>0006-8950</issn><issn>1460-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0M9LHDEUwPFQlLra3nouQ8GeOjUvPycHDyK1KwhaWqX0El5mMxo7v0x20P73Zt1FoRcP4R3y4YV8CfkA9CtQww9cxNAf4P01gHxDZiAULRlItUVmlFJVVkbSHbKb0i2lIDhTb8kOMGUoFWZGDi98DOONj9gWwxiGsCiwx_bap4BF6Av_MGbQ-X6Zwc3UYV-M-b2iGxa-Te_IdoNt8u83c49cnnz7dTwvz86_nx4fnZW10GpZqkoYpz3UUhtWLZDr2glnJGrWOGSce-lWpwbpHG8U4xK8qRomhABEyvfI5_XeMQ53k09L24VU-7bF3g9TsppDxQSYVyEYQanWOsNP_8HbYYr55ysjcyYqV9u-rFEdh5Sib-yYW2D8Z4HaVXz7FN-u42f-cbNzcp1fvOBN7Qz2NwBTjW0Tsa9DenHCMDAVZFeuXUhL__B8j_GvVZpraee__9j51Q8pjVL2J38EgkCcAA</recordid><startdate>20030501</startdate><enddate>20030501</enddate><creator>Tegeder, Irmgard</creator><creator>Meier, Silke</creator><creator>Burian, Maria</creator><creator>Schmidt, Helmut</creator><creator>Geisslinger, Gerd</creator><creator>Lötsch, Jörn</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20030501</creationdate><title>Peripheral opioid analgesia in experimental human pain models</title><author>Tegeder, Irmgard ; Meier, Silke ; Burian, Maria ; Schmidt, Helmut ; Geisslinger, Gerd ; Lötsch, Jörn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-6849b7e1c57928da37cb4b95a72fba233e5b3e5bc15bb3f62351e98f24441aa03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Analgesics - therapeutic use</topic><topic>Anesthesia</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Cold Temperature - adverse effects</topic><topic>Cross-Over Studies</topic><topic>DOMS = delayed onset of muscle soreness</topic><topic>Double-Blind Method</topic><topic>Electric Stimulation</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperalgesia - drug therapy</topic><topic>Hyperalgesia - etiology</topic><topic>inflammation</topic><topic>Local anesthesia. Pain (treatment)</topic><topic>M6G = morphine‐6‐glucuronide</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Morphine</topic><topic>Morphine Derivatives - therapeutic use</topic><topic>morphine‐6‐glucuronide</topic><topic>Muscle Contraction</topic><topic>pain</topic><topic>Peripheral Nerves - drug effects</topic><topic>Peripheral Nerves - metabolism</topic><topic>peripheral opioid receptor</topic><topic>Receptors, Opioid - drug effects</topic><topic>VAS = visual analogue scale</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tegeder, Irmgard</creatorcontrib><creatorcontrib>Meier, Silke</creatorcontrib><creatorcontrib>Burian, Maria</creatorcontrib><creatorcontrib>Schmidt, Helmut</creatorcontrib><creatorcontrib>Geisslinger, Gerd</creatorcontrib><creatorcontrib>Lötsch, Jörn</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain (London, England : 1878)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tegeder, Irmgard</au><au>Meier, Silke</au><au>Burian, Maria</au><au>Schmidt, Helmut</au><au>Geisslinger, Gerd</au><au>Lötsch, Jörn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peripheral opioid analgesia in experimental human pain models</atitle><jtitle>Brain (London, England : 1878)</jtitle><addtitle>Brain</addtitle><date>2003-05-01</date><risdate>2003</risdate><volume>126</volume><issue>5</issue><spage>1092</spage><epage>1102</epage><pages>1092-1102</pages><issn>0006-8950</issn><eissn>1460-2156</eissn><coden>BRAIAK</coden><abstract>This placebo‐controlled, double‐blind crossover study assessed whether exclusive activation of peripheral opioid receptors results in significant pain reduction. To achieve opioid activity restricted to the periphery, we used a short‐term (2 h) low dose infusion of morphine‐6‐β‐glucuronide (M6G) because M6G does not pass the blood–brain barrier during this time in amounts sufficient to induce CNS effects. The lack of central opioid effects of M6G was confirmed by a lack of change of the pupil size and absence of other opioid‐related CNS effects. As a positive control, morphine was infused at a dosage that definitely produced CNS effects. This was evident by a rapid decrease of the pupil size and by other typical opioid‐related side effects including nausea, vomiting, itchiness, hiccup and sedation. Three different pain models were employed to evaluate the analgesic effects: (i) cutaneous inflammatory hyperalgesia induced by briefly freezing a small skin area to –30°C (‘freeze lesion’); (ii) muscle hyperalgesia induced by a series of concentric and eccentric muscle contractions (DOMS model; delayed onset of muscle soreness); and (iii) pain induced by electrical current (5 Hz sinus stimuli of 0–10 mA). M6G significantly reduced cutaneous hyperalgesia in the ‘freeze lesion’ model as assessed with von Frey hairs. It also reduced muscle hyperalgesia in the DOMS model. Electrical pain, however, was not affected by M6G. Morphine was significantly more active in the ‘freeze lesion’ and DOMS model, and also significantly increased the electrical pain threshold and tolerance. Subcutaneous tissue concentrations of M6G and morphine as assessed with microdialysis were about half those of the respective plasma concentrations. The results of the study indicate that M6G has antihyperalgesic effects in inflammatory pain through activation of peripheral opioid receptors. Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12690049</pmid><doi>10.1093/brain/awg115</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-8950
ispartof Brain (London, England : 1878), 2003-05, Vol.126 (5), p.1092-1102
issn 0006-8950
1460-2156
language eng
recordid cdi_proquest_miscellaneous_73182419
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects Adult
Analgesics - therapeutic use
Anesthesia
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Cold Temperature - adverse effects
Cross-Over Studies
DOMS = delayed onset of muscle soreness
Double-Blind Method
Electric Stimulation
Female
Humans
Hyperalgesia - drug therapy
Hyperalgesia - etiology
inflammation
Local anesthesia. Pain (treatment)
M6G = morphine‐6‐glucuronide
Male
Medical sciences
Morphine
Morphine Derivatives - therapeutic use
morphine‐6‐glucuronide
Muscle Contraction
pain
Peripheral Nerves - drug effects
Peripheral Nerves - metabolism
peripheral opioid receptor
Receptors, Opioid - drug effects
VAS = visual analogue scale
title Peripheral opioid analgesia in experimental human pain models
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T09%3A01%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peripheral%20opioid%20analgesia%20in%20experimental%20human%20pain%20models&rft.jtitle=Brain%20(London,%20England%20:%201878)&rft.au=Tegeder,%20Irmgard&rft.date=2003-05-01&rft.volume=126&rft.issue=5&rft.spage=1092&rft.epage=1102&rft.pages=1092-1102&rft.issn=0006-8950&rft.eissn=1460-2156&rft.coden=BRAIAK&rft_id=info:doi/10.1093/brain/awg115&rft_dat=%3Cproquest_cross%3E19400777%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195432059&rft_id=info:pmid/12690049&rfr_iscdi=true